Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc.

Bernstein analyst Courtney Breen maintained a Hold rating on Amgen yesterday and set a price target of $335.00. The company’s shares closed yesterd...

Bernstein Reaffirms Their Hold Rating on Amgen (AMGN)

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. has stopped a late stage study testing bemarituzumab in advanced ...

Amgen Halts Bemarituzumab Gastric Cancer Trial, Shifting Oncology Expectations

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has completed a Phase 1 trial that tests how its obesity d...

Amgen Advances Obesity Pipeline With Fresh Data on AMG 133 Injection Formats

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. has halted a key Phase 3 maintenance study known as ROCKET-ASCEND...

Amgen’s Rocatinlimab Eczema Trial Termination Jolts Investor Expectations

Citi analyst Geoff Meacham maintained a Hold rating on Amgen today and set a price target of $345.00. Meacham covers the Healthcare sector, focusin...

Citi Sticks to Its Hold Rating for Amgen (AMGN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Denali Therapeutics (DNLI) and Amgen (AMGN). Denali Therapeutics ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Denali Therapeutics (DNLI) and Amgen (AMGN)

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has completed a Phase 2 study called “A Phase 2, Randomize...

Amgen’s Rocatinlimab Asthma Trial Reaches Phase 2 Finish Line

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen’s latest study looks at how its obesity drug candidate works with rout...

Amgen’s AMG 133 Trial Adds a New Data Point in the Obesity Drug Race

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) is running a new early-stage trial titled “An Open-Label, ...

Amgen Refines Its PCSK9 Franchise with New Evolocumab Bioavailability Study

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Oruka Therapeutics (ORKA) and Hims &...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Oruka Therapeutics (ORKA) and Hims & Hers Health (HIMS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN), BridgeBio Pharma (BBIO) and Jazz Pharm...

Analysts’ Top Healthcare Picks: Amgen (AMGN), BridgeBio Pharma (BBIO)

Schwab U.S. Dividend Equity ETF ($SCHD) has climbed about 18% since the start of the year. Yet TipRanks’ AI analyst sees the exchange-traded fund (...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AMGN	$378.04	+1.76%	646.72K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AMGN	$378.04	+1.8%	646.72K
3
4
5
6

AMGN

AMGN

Get Amgen Inc. Data in Excel

Get Amgen Inc. Data in Excel